Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI.
Claassens DMF, Vos GJA, Bergmeijer TO, Hermanides RS, van 't Hof AWJ, van der Harst P, Barbato E, Morisco C, Tjon Joe Gin RM, Asselbergs FW, Mosterd A, Herrman JR, Dewilde WJM, Janssen PWA, Kelder JC, Postma MJ, de Boer A, Boersma C, Deneer VHM, Ten Berg JM. Claassens DMF, et al. Among authors: dewilde wjm. N Engl J Med. 2019 Oct 24;381(17):1621-1631. doi: 10.1056/NEJMoa1907096. Epub 2019 Sep 3. N Engl J Med. 2019. PMID: 31479209 Clinical Trial.
Antithrombotic dilemma.
Dewilde W, ten Berg JM. Dewilde W, et al. Future Cardiol. 2007 Sep;3(5):511-3. doi: 10.2217/14796678.3.5.511. Future Cardiol. 2007. PMID: 19804305
Triple therapy: the future or from the past?
Dewilde W, Breet N, Ten Berg J. Dewilde W, et al. EuroIntervention. 2010 Jan;5(6):650; author reply 651. doi: 10.4244/eijv5i6a106. EuroIntervention. 2010. PMID: 20142212 No abstract available.
Triple therapy: triple safety or triple danger?
Dewilde W, Breet N, Ten Berg J. Dewilde W, et al. Am J Cardiol. 2010 Feb 15;105(4):579. doi: 10.1016/j.amjcard.2009.09.051. Am J Cardiol. 2010. PMID: 20152257 No abstract available.
Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.
Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, Adriaenssens T, Vrolix M, Heestermans AA, Vis MM, Tijsen JG, van 't Hof AW, ten Berg JM; WOEST study investigators. Dewilde WJ, et al. Lancet. 2013 Mar 30;381(9872):1107-15. doi: 10.1016/S0140-6736(12)62177-1. Epub 2013 Feb 13. Lancet. 2013. PMID: 23415013 Clinical Trial.
CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study.
Bergmeijer TO, Janssen PW, Schipper JC, Qaderdan K, Ishak M, Ruitenbeek RS, Asselbergs FW, van 't Hof AW, Dewilde WJ, Spanó F, Herrman JP, Kelder JC, Postma MJ, de Boer A, Deneer VH, ten Berg JM. Bergmeijer TO, et al. Am Heart J. 2014 Jul;168(1):16-22.e1. doi: 10.1016/j.ahj.2014.03.006. Epub 2014 Mar 21. Am Heart J. 2014. PMID: 24952855 Clinical Trial.
Uninterrupted oral anticoagulation versus bridging in patients with long-term oral anticoagulation during percutaneous coronary intervention: subgroup analysis from the WOEST trial.
Dewilde WJ, Janssen PW, Kelder JC, Verheugt FW, De Smet BJ, Adriaenssens T, Vrolix M, Brueren GB, Van Mieghem C, Cornelis K, Vos J, Breet NJ, ten Berg JM. Dewilde WJ, et al. EuroIntervention. 2015 Aug;11(4):381-90. doi: 10.4244/EIJY14M06_07. EuroIntervention. 2015. PMID: 24970794 Free article. Clinical Trial.
60 results